Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
Primary liver cancers are the sixth most common malignancies worldwide, with hepatocellular
carcinoma (HCC) accounting for approximately 80% of them. The Barcelona Clinic Liver Cancer
(BCLC) classification is widely used in the management of HCC. At the time of diagnosis,
fewer than 30% of the patients qualify for resection or transplant due to the large size or
multiplicity of the lesions, background chronic liver disease, and other comorbidities.
However, the recent spread of surveillance has led to early detection of hepatocellular
carcinoma (HCC), and the chance of receiving local treatment has increased. There are several
options to treat small HCCs, including surgical resection, chemical ablation,
transplantation, and percutaneous ablation (RFA/MWA).
Today, percutaneous ablation plays a key role in the treatment of early-stage HCC because it
is less invasive than surgical resection and has a good efficacy. However, targeting of
lesions under USG alone may be misleading as there may be an enhancing component which is not
seen on plain ultrasound. To overcome this problem contrast enhanced ultrasound may be used
intra-procedurally, however conventional ultrasound contrast agents show washout by 5 minutes
from the system.
In this study, the investigators prospectively analyze patients undergoing ablation with the
help of precise needle placement using a Kupffer phase ultrasound contrast agent
(perfluorobutane) and their post procedure response assessment.